PALB2 mutation
|
Pancreatic Ductal Adenocarcinoma
|
PALB2 mutation
|
Pancreatic Ductal Adenocarcinoma
|
ipilimumab + niraparib Sensitive: C3 – Early Trials
ASCO 2022 - 3 days (NewC3)
|
ipilimumab + niraparib Sensitive: C3 – Early Trials
ASCO 2022 - 3 days - (New C3)
|
PALB2 mutation
|
Pancreatic Adenocarcinoma
|
PALB2 mutation
|
Pancreatic Adenocarcinoma
|
cisplatin + gemcitabine Sensitive: A2 - Guideline
|
cisplatin + gemcitabine Sensitive: A2 - Guideline
|
PALB2 mutation
|
Prostate Cancer
|
PALB2 mutation
|
Prostate Cancer
|
olaparib Sensitive: A2 - Guideline
|
olaparib Sensitive: A2 - Guideline
|
PALB2 mutation
|
HER2 Negative Breast Cancer
|
PALB2 mutation
|
HER2 Negative Breast Cancer
|
talazoparib Sensitive: A2 - Guideline
|
talazoparib Sensitive: A2 - Guideline
|
PALB2 mutation
|
HER2 Negative Breast Cancer
|
PALB2 mutation
|
HER2 Negative Breast Cancer
|
olaparib Sensitive: A2 - Guideline
|
olaparib Sensitive: A2 - Guideline
|
PALB2 mutation
|
Pancreatic Adenocarcinoma
|
PALB2 mutation
|
Pancreatic Adenocarcinoma
|
rucaparib Sensitive: A2 - Guideline
|
rucaparib Sensitive: A2 - Guideline
|
PALB2 mutation
|
Ovarian Cancer
|
PALB2 mutation
|
Ovarian Cancer
|
olaparib Sensitive: B - Late Trials
|
olaparib Sensitive: B - Late Trials
|
PALB2 mutation
|
Breast Cancer
|
PALB2 mutation
|
Breast Cancer
|
CX-5461 Sensitive: B - Late Trials
|
CX-5461 Sensitive: B - Late Trials
|
PALB2 mutation
|
Ovarian Cancer
|
PALB2 mutation
|
Ovarian Cancer
|
CX-5461 Sensitive: B - Late Trials
|
CX-5461 Sensitive: B - Late Trials
|
PALB2 mutation
|
Pancreatic Cancer
|
PALB2 mutation
|
Pancreatic Cancer
|
ABT-888 Sensitive: C2 – Inclusion Criteria
|
ABT-888 Sensitive: C2 – Inclusion Criteria
|
PALB2 mutation
|
Pancreatic Cancer
|
PALB2 mutation
|
Pancreatic Cancer
|
rucaparib Sensitive: C2 – Inclusion Criteria
|
rucaparib Sensitive: C2 – Inclusion Criteria
|
PALB2 mutation
|
Breast Cancer
|
PALB2 mutation
|
Breast Cancer
|
olaparib Sensitive: C2 – Inclusion Criteria
|
olaparib Sensitive: C2 – Inclusion Criteria
|
PALB2 mutation
|
Urothelial Cancer
|
PALB2 mutation
|
Urothelial Cancer
|
olaparib Sensitive: C2 – Inclusion Criteria
|
olaparib Sensitive: C2 – Inclusion Criteria
|
PALB2 mutation
|
HER2 Negative Breast Cancer
|
PALB2 mutation
|
HER2 Negative Breast Cancer
|
durvalumab Sensitive: C2 – Inclusion Criteria
|
durvalumab Sensitive: C2 – Inclusion Criteria
|
PALB2 mutation
|
Triple Negative Breast Cancer
|
PALB2 mutation
|
Triple Negative Breast Cancer
|
everolimus Sensitive: C3 – Early Trials
|
everolimus Sensitive: C3 – Early Trials
|
PALB2 mutation
|
Pancreatic Ductal Adenocarcinoma
|
PALB2 mutation
|
Pancreatic Ductal Adenocarcinoma
|
FOLFIRINOX Sensitive: C3 – Early Trials
|
FOLFIRINOX Sensitive: C3 – Early Trials
|
PALB2 mutation
|
Hormone Receptor Positive Breast Cancer
|
PALB2 mutation
|
Hormone Receptor Positive Breast Cancer
|
lenvatinib Resistant: C3 – Early Trials
|
lenvatinib Resistant: C3 – Early Trials
|
PALB2 mutation
|
Pancreatic Cancer
|
PALB2 mutation
|
Pancreatic Cancer
|
oxaliplatin Sensitive: C3 – Early Trials
|
oxaliplatin Sensitive: C3 – Early Trials
|
PALB2 mutation
|
Prostate Cancer
|
PALB2 mutation
|
Prostate Cancer
|
PARP inhibitor Sensitive: C3 – Early Trials
|
PARP inhibitor Sensitive: C3 – Early Trials
|
PALB2 mutation
|
Pancreatic Ductal Adenocarcinoma
|
PALB2 mutation
|
Pancreatic Ductal Adenocarcinoma
|
cisplatin + gemcitabine Sensitive: C3 – Early Trials
|
cisplatin + gemcitabine Sensitive: C3 – Early Trials
|
PALB2 mutation
|
Endometrial Cancer
|
PALB2 mutation
|
Endometrial Cancer
|
rucaparib + E 3810 Sensitive: C4 – Case Studies
|
rucaparib + E 3810 Sensitive: C4 – Case Studies
|
PALB2 mutation
|
Triple Negative Breast Cancer
|
PALB2 mutation
|
Triple Negative Breast Cancer
|
carboplatin + docetaxel Sensitive: D – Preclinical
|
carboplatin + docetaxel Sensitive: D – Preclinical
|